HROWHARROW, INC.同业对比
HARROW, INC. 与Pharmaceutical Preparations的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Pharmaceutical Preparations)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HROW本股 | $1.2B#8 | — | 81.8x#12 | 4.6x#4 | 36.4%#1 | 70.6%#2 | 11.2%#1 | -33.8%#7 | 13.2%#2 | 6#1 | -23.1%#11 | — |
| RARE | $1.4B#1 | — | — | 2.1x#2 | 20.2%#3 | -1.1%#4 | -79.5%#4 | — | — | — | -49.5%#13 | — |
| DMRA | $1.4B#2 | 3.0x#2 | 2.7x#4 | — | — | -878.8%#13 | — | -40.7%#9 | — | — | 675.3%#3 | — |
| TRAX | $1.4B#3 | — | 8.3x#11 | — | — | — | — | 0.0%#1 | — | — | — | — |
| AVBP | $1.4B#4 | — | 3.8x#7 | — | — | -106.6%#11 | — | -45.3%#10 | — | — | 62.0%#7 | — |
| LBRX | $1.4B#5 | 1.8x#1 | 4.1x#8 | — | — | 60.1%#3 | — | -7.6%#4 | — | — | 157.7%#5 | — |
| OMER | $1.3B#6 | 10.7x#3 | — | 18.1x#5 | -34.0%#5 | 97.9%#1 | -166.4%#5 | — | -151.8%#6 | — | 353.6%#4 | — |
| ORIC | $1.3B#7 | — | 3.5x#6 | — | — | -1.3%#5 | — | -34.0%#8 | -40.4%#4 | — | 22.6%#9 | — |
| AKTS | $1.2B#9 | — | 2.5x#3 | — | — | — | — | 0.0%#1 | — | — | 24872.7%#1 | — |
| ANRO | $1.2B#10 | — | 5.5x#9 | — | — | -2.9%#6 | — | -28.8%#5 | — | — | 704.3%#2 | — |
| OPK | $1.2B#11 | — | 1.0x#1 | 2.0x#1 | -14.9%#4 | -324.0%#12 | -19.3%#3 | -19058.1%#12 | -13.3%#3 | 4#2 | 16.1%#10 | — |
| SPTX | $1.2B#12 | — | 2.8x#5 | — | — | — | — | 0.0%#1 | — | — | — | — |
| MNKD | $1.2B#13 | — | — | 3.3x#3 | 22.2%#2 | -78.7%#9 | 11.1%#2 | — | 2283.8%#1 | — | -33.5%#12 | — |
| SVRA | $1.1B#14 | — | 7.7x#10 | 4329.1x#6 | — | -23.9%#8 | -48072.8%#6 | -82.7%#11 | -93.6%#5 | — | 50.8%#8 | — |
| JBIO | $1.1B#15 | — | 2.5x#2 | — | — | -83.0%#10 | — | -29.0%#6 | — | — | 144.4%#6 | — |
| OBX | $1.1B#16 | — | — | — | — | -21.1%#7 | — | — | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-18。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议